fda compounding glp-1 enforcement news to Restrict Ingredients Used in Mass-Marketed Compounded GLP-1s, Crack Down on Misleading Ads Fifth Circuit probes FDA ban

However, findings from another case report investigating semaglutide in MC4R -deficient obesity [77] indicated variability in treatment response

& Bao, Y

Differences fall in the dispensing pathway, brand-name versus compounded options, and the subscription terms, not in the drugs mechanism of action

& Poupon, M

So its the same center when you have an addiction, when you have an opioid or when you drink alcohol, its the same center that gives you the same message: Get this again. GLP-1 drugs have rapidly turned into blockbusters for the companies that make them, also worrying insurance companies with their not-insubstantial price tags